Home › Viral Infections
Viral Infections clinical trials recruiting in the U.S.
31 studies for Viral Infections are recruiting participants at sites across the United States.
Viruses cause familiar infections such as the common cold, but they also cause severe illnesses. Learn more about viral infections and their symptoms.
Cities with the most studies
- Washington, DC12 studies
- Houston, TX6 studies
- Boston, MA6 studies
- Baltimore, MD5 studies
- Hialeah, FL5 studies
- Dallas, TX4 studies
- Atlanta, GA4 studies
- Columbus, OH4 studies
- Cincinnati, OH4 studies
- Salt Lake City, UT3 studies
- Omaha, NE3 studies
- Los Angeles, CA3 studies
- Tampa, FL3 studies
- Boise, ID3 studies
- Miami, FL3 studies
- St. Louis, MO3 studies
- Durham, NC3 studies
- San Francisco, CA3 studies
- New York City, NY3 studies
By state
- Alabama3 studies
- California11 studies
- Colorado3 studies
- District of Columbia5 studies
- Florida6 studies
- Georgia5 studies
- Idaho3 studies
- Illinois3 studies
- Kentucky3 studies
- Louisiana3 studies
- Maryland14 studies
- Massachusetts6 studies
- Michigan3 studies
- Missouri4 studies
- Nebraska3 studies
- New York6 studies
- North Carolina5 studies
- Ohio9 studies
- Pennsylvania4 studies
- South Carolina3 studies
- Texas9 studies
- Utah4 studies
- Virginia4 studies
Recently updated studies
A Study of COVID-19 Vaccine(s) in Children and Adults
RecruitingPhase 3Healthy volunteers welcome
Ages 5 and older · All sexes · Updated Sep 28, 2026 · NCT07798648Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer
RecruitingObservational study
Ages 18 to 120 · All sexes · Updated Sep 28, 2026 · NCT00006518The Natural History of Severe Viral Infections and Characterization of Immune Defects in Patients Without Known Immunocompromise
RecruitingObservational study
Ages 2 to 100 · All sexes · Updated Sep 28, 2026 · NCT01011712A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease
RecruitingPhase 3
Ages 12 and older · All sexes · Updated Sep 25, 2026 · NCT06679140A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07013474Phase 1 Challenge Study Using rDEN2delta30-7169 to Evaluate Host-Pathogen Interactions in Primary, Homotypic, and Heterotypic Dengue Virus Infection
RecruitingPhase 1Healthy volunteers welcome
Ages 18 to 50 · All sexes · Updated Sep 25, 2026 · NCT07706686Study of AHB-137 in Chronic Hepatitis B (CHB) Participants in North America and Europe Regions
RecruitingPhase 2
Ages 18 to 65 · All sexes · Updated Sep 24, 2026 · NCT07654283A Clinical Study to Investigate the Safety and Immunogenicity of rVSV∆G-SUDV-GP, a Sudan Virus (SUDV) Vaccine for the Prevention of SUDV Disease in Adults in Good General Health
RecruitingPhase 1Healthy volunteers welcome
Ages 18 to 50 · All sexes · Updated Sep 21, 2026 · NCT07565090Evaluating the Dose, Safety, Tolerability, and Immunogenicity of Mosaic Hexavalent Influenza Vaccine VRCFLUMOS0116-00-VP (FluMos-v2) With and Without ALFQ Adjuvant in Healthy Adults
RecruitingPhase 1Healthy volunteers welcome
Ages 18 to 50 · All sexes · Updated Sep 15, 2026 · NCT06863142Viral Infections in Healthy and Immunocompromised Hosts
RecruitingObservational studyHealthy volunteers welcome
6 Months – 120 Years · All sexes · Updated Sep 14, 2026 · NCT01306084Acute Infection in Mitochondrial Disease: Metabolism, Infection and Immunity
RecruitingObservational studyHealthy volunteers welcome
2 Months – 115 Years · All sexes · Updated Sep 10, 2026 · NCT04419870HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
RecruitingPhase 1
36 Months – 22 Years · All sexes · Updated Sep 4, 2026 · NCT03911388Donor-Derived Viral Specific T-cells (VSTs)
RecruitingPhase 1/2
4 Weeks · All sexes · Updated Sep 4, 2026 · NCT02048332Third Party Viral Specific T-cells (VSTs)
RecruitingPhase 2
2 Days · All sexes · Updated Sep 4, 2026 · NCT02532452Trial of Scheduled Versus Treatment Administration of Donor-Derived Viral Specific T-cells for Viral Infections After Stem Cell Transplant
RecruitingPhase 2
All ages · All sexes · Updated Sep 4, 2026 · NCT04230356Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 28, 2026 · NCT05624450A Phase 1/2A, Randomized Study of a T Follicular Helper (TFH)-Targeting Genetic Vaccine Strategy Designed to Induce Broad, Durable Immune Responses
RecruitingPhase 1/2Healthy volunteers welcome
Ages 40 to 64 · All sexes · Updated Aug 18, 2026 · NCT06810934A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 11, 2026 · NCT07214571A Study to Learn About a COVID-19 Vaccine in Healthy Adults 18 Through 64 Years of Age
RecruitingPhase 4Healthy volunteers welcome
Ages 18 to 64 · All sexes · Updated Aug 7, 2026 · NCT07730450Genetic Studies of Chronic Active Epstein-Barr Disease
RecruitingObservational study
Ages 1 to 120 · All sexes · Updated Jul 28, 2026 · NCT00032513TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
RecruitingPhase 1
All ages · All sexes · Updated Jun 11, 2026 · NCT04013802Treatment of Refractory BK Infections With Related Donor BK Specific Cytotoxic T-cells (CTLs)
RecruitingPhase 1/2
1 Month – 79 Years · All sexes · Updated Apr 15, 2026 · NCT04197596A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations
RecruitingPhase 4Healthy volunteers welcome
6 Months · All sexes · Updated Mar 27, 2026 · NCT06585241Microbial Cell-free Metagenomic Sequencing for Suspected Infections in Adult Immunocompromised Outpatients
Recruiting
Ages 18 and older · All sexes · Updated Jan 30, 2026 · NCT07110636Adoptive T Lymphocyte Administration for Chronic Norovirus Treatment in Immunocompromised Hosts
RecruitingPhase 1
3 Months – 80 Years · All sexes · Updated Jan 26, 2026 · NCT04691622From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.